BWI: Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta®

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Wednesday, November 24, 2010 08:50 PM IST (03:20 PM GMT)
Editors: General: Consumer interest; Business: Advertising, PR & marketing, Business services, Healthcare, biotechnology & pharmaceutical, Retailers; Healthcare
--------------------------------------------------
Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta®


Mumbai, Maharashtra, India, Wednesday, November 24, 2010 -- (Business Wire India) -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain (DPNP)

Cymbalta® has annual sale of approximately $ 3 billion in the US.

Cymbalta® is a registered trademark of Eli Lilly & Company

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms.

More information about the company can be found at www.sunpharma.com



CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 9867010529 / +91 (22) 66455605, uday.baldota@sunpharma.com
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 9821923797 / +91 (22) 66455606, mira.desai@sunpharma.com

KEYWORDS
CONSUMER, MARKETING, BUSINESS SERVICES, HEALTHCARE, RETAIL, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com